Compare ATCH & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | LTRN |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 31.5M |
| IPO Year | 2024 | 2020 |
| Metric | ATCH | LTRN |
|---|---|---|
| Price | $0.20 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.4M | 971.6K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $1.11 |
| 52 Week High | $1.92 | $5.74 |
| Indicator | ATCH | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 26.94 |
| Support Level | $0.18 | N/A |
| Resistance Level | $0.21 | $3.79 |
| Average True Range (ATR) | 0.01 | 0.32 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 70.38 | 20.20 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.